Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.H.S., Duke University 2001
  • Fellow in Gastroenterology, Medicine, Duke University 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University 1997 - 1998
  • Fellow in Gastroenterology, Medicine, Duke University 1996 - 1997
  • Medical Resident, Medicine, Duke University 1993 - 1996
  • M.D., Duke University 1993
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2011 - 2016
  • Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2010 - 2011
  • Assistant Professor of Medicine, Medicine, Gastroenterology, Medicine 2001 - 2009
  • Associate in the Department of Medicine, Medicine, Gastroenterology, Medicine 2000 - 2001
  • Associate in the Department of Medicine, Medicine, Clinical Science Departments 1997 - 1998
• Recognition
• 

  In the News

  • AUG 21, 2019

    Pratt School of Engineering

    Hungry for Innovation: How a MEDx Dinner Led to a Newly Patented Medical Tool

  • JUN 17, 2015

    WNCN

    Pill-form Hepatitis C treatment giving patients hope

  • MAY 12, 2015

    Interferon-Free Therapy Clears Hepatitis C in 93 Percent of Patients in Trial

  • JUN 13, 2014

    The News & Observer

    New hepatitis C wonder drug shakes up the health care industry
• 

  Awards & Honors

  • Best Medicine Grand Rounds. Duke Department of Medicine. 2011
• Expertise
• 

  Subject Headings

  • Cholangitis, Sclerosing
  • Hepatitis C
  • Liver Diseases
  • Liver Transplantation
• 

  Global Scholarship

  • Research

    • United States of America (Country) 
• Research
• 

  Selected Grants

  • GS-US-428-4194 2019 - 2024
  • CymaBay CB8025-31735 2019 - 2023
  • Proteus HCV - PB-WOTFORHEPC 2017 - 2022
  • Novartis - AMBER - VAY736 2018 - 2021
  • T32-Diversity: NRSA Diversity Supplement Award awarded by National Institutes of Health 1988 - 2021
  • VTEU 13-0053 Task Area C awarded by National Institutes of Health 2014 - 2020
  • Gilead 428-4025 2017 - 2020
  • The Impact of Race, Ethnicity, and Socioeconomic Status on Listing for Liver Transplant after Referral awarded by American Association for the Study of Liver Diseases 2018 - 2020
  • HBV Clinical Research Network Site Application_Subcontract to UNC awarded by University of North Carolina - Chapel Hill 2015 - 2020
  • Heart/Lung Transplant Study 2016 - 2020
  • Smart-C 2018 - 2019
  • Sulfasalazine in PSC awarded by Brigham and Women's Hospital 2018 - 2019
  • Gilead 427-4024 2017 - 2019
  • TaiwanJ JKB 122AIH 2015 - 2019
  • HBV Clinical Research Network Site Application_Subcontract to UNC awarded by University of North Carolina - Chapel Hill 2015 - 2019
  • RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse awarded by National Institutes of Health 2013 - 2019
  • An Observational Cohort Study of the Use of Avatrombopag in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure 2018 - 2019
  • DAA-Salvage Therapy awarded by University of Florida 2017 - 2019
  • Gilead 342-4022 2017 - 2019
  • NGM 15-0106 2015 - 2019
  • Abbvie M13-596 2016 - 2019
  • Gilead 337-1746 2015 - 2018
  • The Impact of Increasing Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients awarded by American Association for the Study of Liver Diseases 2017 - 2018
  • MK 3682-011 2015 - 2017
  • AbbVie M14-868 2014 - 2017
  • Merck MK-5172-017-02 2015 - 2017
  • Regulation of T cell exhaustion by microRNA-720 awarded by National Institutes of Health 2015 - 2017
  • Merck/MSD MK-5172-065-00 2014 - 2017
  • NGM 14-0104 2014 - 2017
  • A Phase 2 open-label study in patients with recurrent Genotype 1 Hepatitis 2014 - 2017
  • GS-US-342-1137 2014 - 2017
  • Evidera PSC 2014 - 2016
  • BMS AI443-102-0016 A Phase 3 Evaluation 2013 - 2015
  • BMS Muir, AI443-113 2013 - 2015
  • HPN-100-022 2014 - 2015
  • Pilot Study to Assess Changes in Immuneregulation with Phase of Chronic HBV Infection and Antiviral Therapy 2013 - 2015
  • Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients awarded by National Institutes of Health 2011 - 2015
  • VTEU 13-0053 Task Area B awarded by National Institutes of Health 2014 - 2015
  • Patient self-management and gene guided therapy for CHC awarded by National Institutes of Health 2012 - 2015
  • A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir 2013 - 2014
  • Gilead GS-US-334-0107 LOI 2012
  • Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse awarded by National Institutes of Health 2008 - 2011
  • Uncertainity and Watchful Waiting in Chronic Hepatitis C awarded by National Institutes of Health 2005 - 2009
  • Interferon-y for the treatment of chronic HCV infection awarded by National Institutes of Health 2001 - 2004
• 

  Industry Relationships

  • AbbVie
  • Axovant
  • Blade Therapeutics
  • Delcath Systems
  • Dova Pharmaceuticals
  • Enanta
  • Gilead Sciences, Inc.
  • Merck
  • Precision Bioscience
  • ProQR Therapeutics
  • Shionogi Pharma
  • Shire Pharmaceuticals
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Younossi, Zobair M., Maria Stepanova, Eric J. Lawitz, K Rajender Reddy, Vincent Wai-Sun Wong, Alessandra Mangia, Andrew J. Muir, et al. “Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life..” Am J Gastroenterol 114, no. 10 (October 2019): 1636–41. https://doi.org/10.14309/ajg.0000000000000375.
       Full Text  Link to Item
    • Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, et al. “The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis..” Hepatology 70, no. 3 (September 2019): 788–801. https://doi.org/10.1002/hep.30509.
       Full Text  Link to Item
    • Di Bisceglie, Adrian M., Wendy C. King, Mauricio Lisker-Melman, Mandana Khalili, Steven H. Belle, Jordan J. Feld, Marc G. Ghany, et al. “Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B..” J Viral Hepat 26, no. 7 (July 2019): 856–65. https://doi.org/10.1111/jvh.13104.
       Full Text  Link to Item
    • Muir, Andrew J. “Is Magnetic Resonance Cholangiopancreatography Worth a Thousand Words in Determining Prognoses of Patients With Primary Sclerosing Cholangitis?.” Clin Gastroenterol Hepatol, May 8, 2019. https://doi.org/10.1016/j.cgh.2019.04.067.
       Full Text  Link to Item
    • Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, et al. “The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials..” Hepatology, April 16, 2019. https://doi.org/10.1002/hep.30664.
       Full Text  Link to Item
    • Younossi, Zobair M., Maria Stepanova, Ira Jacobson, Andrew J. Muir, Stanislas Pol, Stefan Zeuzem, Ziad Younes, et al. “Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes..” Clin Infect Dis, April 5, 2019. https://doi.org/10.1093/cid/ciz243.
       Full Text  Link to Item
    • Hirschfield, Gideon M., Olivier Chazouillères, Joost P. Drenth, Douglas Thorburn, Stephen A. Harrison, Charles S. Landis, Marlyn J. Mayo, et al. “Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial..” J Hepatol 70, no. 3 (March 2019): 483–93. https://doi.org/10.1016/j.jhep.2018.10.035.
       Full Text  Link to Item
    • Muir, Andrew J., Cynthia Levy, Harry L. A. Janssen, Aldo J. Montano-Loza, Mitchell L. Shiffman, Stephen Caldwell, Velimir Luketic, et al. “Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease..” Hepatology 69, no. 2 (February 2019): 684–98. https://doi.org/10.1002/hep.30237.
       Full Text  Link to Item
    • Bailey, D. E., A. J. Muir, J. A. Adams, N. M. Thygeson, H. Williams, M. P. Cary, and R. A. Anderson. “Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic Illness.” Sage Open 9, no. 1 (January 1, 2019). https://doi.org/10.1177/2158244018824461.
       Full Text
    • Younossi, Zobair, Maria Stepanova, Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, et al. “The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options..” J Hepatol 69, no. 6 (December 2018): 1365–70. https://doi.org/10.1016/j.jhep.2018.08.013.
       Full Text  Link to Item
    • Harrison, Stephen A., Manal F. Abdelmalek, Stephen Caldwell, Mitchell L. Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J. Lawitz, et al. “Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis..” Gastroenterology 155, no. 4 (October 2018): 1140–53. https://doi.org/10.1053/j.gastro.2018.07.006.
       Full Text  Link to Item
    • Patel, Yuval A., Jacqueline B. Henson, Julius M. Wilder, Jiayin Zheng, Schein-Chung Chow, Carl L. Berg, Stuart J. Knechtle, and Andrew J. Muir. “The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis..” Clin Transplant 32, no. 10 (October 2018). https://doi.org/10.1111/ctr.13388.
       Full Text  Link to Item
    • Mayo, Marlyn J., Alan J. Wigg, Barbara A. Leggett, Hays Arnold, Alexander J. Thompson, Martin Weltman, Elizabeth J. Carey, et al. “NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial..” Hepatol Commun 2, no. 9 (September 2018): 1037–50. https://doi.org/10.1002/hep4.1209.
       Full Text  Link to Item
    • Proeschold-Bell, Rae Jean, Donna M. Evon, Christina Makarushka, John B. Wong, Santanu K. Datta, Jia Yao, Ashwin A. Patkar, et al. “The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial..” Contemp Clin Trials 72 (September 2018): 73–85. https://doi.org/10.1016/j.cct.2018.07.003.
       Full Text  Link to Item
    • Nitsche, Bruce, Sara C. Miller, Margaret Giorgio, Carolyn A. Berry, and Andrew Muir. “Improving Hepatitis C Identification: Technology Alone Is Not the Answer..” Health Promot Pract 19, no. 4 (July 2018): 506–12. https://doi.org/10.1177/1524839917725501.
       Full Text  Link to Item
    • Patel, Y. A., and A. J. Muir. “Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits?.” Aliment Pharmacol Ther 47, no. 11 (June 2018): 1553–54. https://doi.org/10.1111/apt.14654.
       Full Text  Link to Item
    • Wilder, Julius M., and Andrew Muir. “Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations..” Expert Opin Pharmacother 19, no. 5 (April 2018): 451–56. https://doi.org/10.1080/14656566.2018.1446945.
       Full Text  Link to Item
    • Collins, Lauren F., Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M. Wilder, Andrew J. Muir, and Susanna Naggie. “Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection..” Open Forum Infect Dis 5, no. 1 (January 2018). https://doi.org/10.1093/ofid/ofx264.
       Full Text  Open Access Copy  Link to Item
    • Jou, Janice H., and Andrew J. Muir. “Hepatocellular Carcinoma Surveillance..” Clin Gastroenterol Hepatol 16, no. 1 (January 2018): 19–20. https://doi.org/10.1016/j.cgh.2017.06.049.
       Full Text  Link to Item
    • Tana, Michele M., and Andrew J. Muir. “Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?.” Clin Gastroenterol Hepatol 16, no. 1 (January 2018): 16–18. https://doi.org/10.1016/j.cgh.2017.06.050.
       Full Text  Link to Item
    • Henson, Jacqueline B., Yuval A. Patel, Julius M. Wilder, Jiayin Zheng, Shein-Chung Chow, Lindsay Y. King, and Andrew J. Muir. “Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis..” Dig Dis Sci 62, no. 11 (November 2017): 3200–3209. https://doi.org/10.1007/s10620-017-4559-1.
       Full Text  Link to Item
    • Patel, Yuval A., Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David DeBrota, Lara Dimick-Santos, Claudia Filozof, et al. “Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum..” Gastroenterology 153, no. 3 (September 2017): 621-625.e7. https://doi.org/10.1053/j.gastro.2017.07.024.
       Full Text  Link to Item
    • Sofue, Keitaro, Lauren M. B. Burke, Viragi Nilmini, Madavi Alagiyawanna, Andrew J. Muir, Kingshuk R. Choudhury, Tracy A. Jaffe, Richard C. Semelka, and Mustafa R. Bashir. “Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5..” J Magn Reson Imaging 46, no. 3 (September 2017): 783–92. https://doi.org/10.1002/jmri.25627.
       Full Text  Link to Item
    • Kwo, Paul Y., Fred Poordad, Armen Asatryan, Stanley Wang, David L. Wyles, Tarek Hassanein, Franco Felizarta, et al. “Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis..” J Hepatol 67, no. 2 (August 2017): 263–71. https://doi.org/10.1016/j.jhep.2017.03.039.
       Full Text  Link to Item
    • Henson, Jacqueline B., Cristal L. Brown, Shein-Chung Chow, and Andrew J. Muir. “Complementary and Alternative Medicine Use in United States Adults With Liver Disease..” J Clin Gastroenterol 51, no. 6 (July 2017): 564–70. https://doi.org/10.1097/MCG.0000000000000617.
       Full Text  Link to Item
    • Henson, Jacqueline B., Yuval A. Patel, Lindsay Y. King, Jiayin Zheng, Shein-Chung Chow, and Andrew J. Muir. “Outcomes of liver retransplantation in patients with primary sclerosing cholangitis..” Liver Transpl 23, no. 6 (June 2017): 769–80. https://doi.org/10.1002/lt.24703.
       Full Text  Link to Item
    • Singh, Siddharth, Andrew J. Muir, Douglas T. Dieterich, and Yngve T. Falck-Ytter. “American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases..” Gastroenterology 152, no. 6 (May 2017): 1544–77. https://doi.org/10.1053/j.gastro.2017.03.016.
       Full Text  Link to Item
    • Bailey, Donald E., Cristina C. Hendrix, Karen E. Steinhauser, Karen M. Stechuchak, Laura S. Porter, Julie Hudson, Maren K. Olsen, et al. “Randomized trial of an uncertainty self-management telephone intervention for patients awaiting liver transplant..” Patient Educ Couns 100, no. 3 (March 2017): 509–17. https://doi.org/10.1016/j.pec.2016.10.017.
       Full Text  Link to Item
    • O’Leary, Jacqueline G., Robert J. Fontana, Kimberly Brown, James R. Burton, Roberto Firpi-Morell, Andrew Muir, Christopher O’Brien, et al. “Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study..” Transpl Int 30, no. 2 (February 2017): 196–208. https://doi.org/10.1111/tri.12896.
       Full Text  Link to Item
    • Naggie, Susanna, and Andrew J. Muir. “Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs..” Annu Rev Med 68 (January 14, 2017): 345–58. https://doi.org/10.1146/annurev-med-052915-015720.
       Full Text  Link to Item
    • Patel, Yuval A., and Andrew J. Muir. “Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals..” Curr Hepatol Rep 15, no. 4 (December 2016): 285–90. https://doi.org/10.1007/s11901-016-0319-5.
       Full Text  Link to Item
    • Patel, Yuval A., and Andrew J. Muir. “Mechanisms of Ascites Development-Reply..” Jama 316, no. 17 (November 1, 2016). https://doi.org/10.1001/jama.2016.15072.
       Full Text  Link to Item
    • Brown, Cristal L., Bradley G. Hammill, Laura G. Qualls, Lesley H. Curtis, and Andrew J. Muir. “Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare..” J Pain Symptom Manage 52, no. 3 (September 2016): 412-419.e1. https://doi.org/10.1016/j.jpainsymman.2016.03.013.
       Full Text  Link to Item
    • Burke, Lauren M. B., Keitaro Sofue, Madavi Alagiyawanna, Viragi Nilmini, Andrew J. Muir, Kingshuk R. Choudhury, Richard C. Semelka, and Mustafa R. Bashir. “Natural history of liver imaging reporting and data system category 4 nodules in MRI..” Abdom Radiol (Ny) 41, no. 9 (September 2016): 1758–66. https://doi.org/10.1007/s00261-016-0762-3.
       Full Text  Link to Item
    • Katrak, Shereen, Lawrence P. Park, Christopher Woods, Andrew Muir, Charles Hicks, and Susanna Naggie. “Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease..” Open Forum Infect Dis 3, no. 3 (September 2016). https://doi.org/10.1093/ofid/ofw173.
       Full Text  Link to Item
    • Patel, Yuval A., and Andrew J. Muir. “Evaluation of New-Onset Ascites..” Jama 316, no. 3 (July 19, 2016): 340–41. https://doi.org/10.1001/jama.2016.7600.
       Full Text  Link to Item
    • Wilder, Julius M., Omobonike O. Oloruntoba, Andrew J. Muir, and Cynthia A. Moylan. “Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation..” Liver Transpl 22, no. 7 (July 2016): 895–905. https://doi.org/10.1002/lt.24452.
       Full Text  Open Access Copy  Link to Item
    • Muir, Andrew J. “State of the State in Gastroenterology..” N C Med J 77, no. 3 (May 2016): 176–79. https://doi.org/10.18043/ncm.77.3.176.
       Full Text  Link to Item
    • Seña, Arlene C., Sarah J. Willis, Alison Hilton, Alexandria Anderson, David A. Wohl, Christopher B. Hurt, and Andrew J. Muir. “Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level..” Public Health Rep 131 Suppl 2 (May 2016): 57–64. https://doi.org/10.1177/00333549161310S210.
       Full Text  Link to Item
    • Sulkowski, Mark S., Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, et al. “Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection..” Gastroenterology 150, no. 2 (February 2016): 419–29. https://doi.org/10.1053/j.gastro.2015.10.013.
       Full Text  Link to Item
    • Wilder, Julius M., Lennox J. Jeffers, Natarajan Ravendhran, Mitchell L. Shiffman, John Poulos, Mark S. Sulkowski, Norman Gitlin, et al. “Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data..” Hepatology 63, no. 2 (February 2016): 437–44. https://doi.org/10.1002/hep.28334.
       Full Text  Open Access Copy  Link to Item
    • Wilder, Julius, Anirudh Saraswathula, Vic Hasselblad, and Andrew Muir. “A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment..” J Natl Med Assoc 108, no. 1 (February 2016): 24–29. https://doi.org/10.1016/j.jnma.2015.12.004.
       Full Text  Open Access Copy  Link to Item
    • Oloruntoba, Omobonike, and Andrew J. Muir. “Integrating daclatasvir into hepatitis c therapy..” Clin Liver Dis (Hoboken) 7, no. 1 (January 2016): 1–4. https://doi.org/10.1002/cld.524.
       Full Text  Link to Item
    • Curry, Michael P., Jacqueline G. O’Leary, Natalie Bzowej, Andrew J. Muir, Kevin M. Korenblat, Jonathan M. Fenkel, K Rajender Reddy, et al. “Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis..” N Engl J Med 373, no. 27 (December 31, 2015): 2618–28. https://doi.org/10.1056/NEJMoa1512614.
       Full Text  Link to Item
    • Muir, Andrew J., and Susanna Naggie. “Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?.” Clin Gastroenterol Hepatol 13, no. 12 (November 2015): 2166–72. https://doi.org/10.1016/j.cgh.2015.07.015.
       Full Text  Link to Item
    • Wilder, Julius M., and Andrew J. Muir. “Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes..” Ther Adv Chronic Dis 6, no. 6 (November 2015): 314–27. https://doi.org/10.1177/2040622315603642.
       Full Text  Open Access Copy  Link to Item
    • Charlton, Michael, Gregory T. Everson, Steven L. Flamm, Princy Kumar, Charles Landis, Robert S. Brown, Michael W. Fried, et al. “Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease..” Gastroenterology 149, no. 3 (September 2015): 649–59. https://doi.org/10.1053/j.gastro.2015.05.010.
       Full Text  Link to Item
    • Shuldiner, Scott R., Li Gong, Andrew J. Muir, Russ B. Altman, and Teri E. Klein. “PharmGKB summary: peginterferon-α pathway..” Pharmacogenet Genomics 25, no. 9 (September 2015): 465–74. https://doi.org/10.1097/FPC.0000000000000158.
       Full Text  Link to Item
    • Ahmad, Tariq, Philip Yin, Jeffrey Saffitz, Paul J. Pockros, Jacob Lalezari, Mitchell Shiffman, Bradley Freilich, et al. “Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C..” Hepatology 62, no. 2 (August 2015): 409–16. https://doi.org/10.1002/hep.27488.
       Full Text  Link to Item
    • Giannini, Edoardo G., Nezam H. Afdhal, Samuel H. Sigal, Andrew J. Muir, K Rajender Reddy, Shanthi Vijayaraghavan, Magdy Elkashab, et al. “Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy..” J Gastroenterol Hepatol 30, no. 8 (August 2015): 1301–8. https://doi.org/10.1111/jgh.12942.
       Full Text  Link to Item
    • Muir, Andrew J. “Understanding the Complexities of Cirrhosis..” Clin Ther 37, no. 8 (August 2015): 1822–36. https://doi.org/10.1016/j.clinthera.2015.05.507.
       Full Text  Link to Item
    • Muir, Andrew J., Fred Poordad, Jacob Lalezari, Gregory Everson, Gregory J. Dore, Robert Herring, Aasim Sheikh, et al. “Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis..” Jama 313, no. 17 (May 5, 2015): 1736–44. https://doi.org/10.1001/jama.2015.3868.
       Full Text  Link to Item
    • Poordad, Fred, William Sievert, Lindsay Mollison, Michael Bennett, Edmund Tse, Norbert Bräu, James Levin, et al. “Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection..” Jama 313, no. 17 (May 5, 2015): 1728–35. https://doi.org/10.1001/jama.2015.3860.
       Full Text  Link to Item
    • Flamm, Steven L., Andrew J. Muir, Michael W. Fried, K Rajender Reddy, David R. Nelson, Natalie H. Bzowej, James C. Sullivan, et al. “Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity..” J Clin Gastroenterol 49, no. 4 (April 2015): 336–44. https://doi.org/10.1097/MCG.0000000000000150.
       Full Text  Link to Item
    • Naggie, Susanna, Keyur Patel, Lan-Yan Yang, Shein-Chung Chow, Victoria Johnson, John R. Guyton, Andrew J. Muir, Mark Sulkowski, and Charles Hicks. “Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals..” Open Forum Infect Dis 2, no. 2 (April 2015). https://doi.org/10.1093/ofid/ofv066.
       Full Text  Link to Item
    • Gordon, Stuart C., Andrew J. Muir, Joseph K. Lim, Brian Pearlman, Curtis K. Argo, Ananthakrishnan Ramani, Benedict Maliakkal, et al. “Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET..” J Hepatol 62, no. 2 (February 2015): 286–93. https://doi.org/10.1016/j.jhep.2014.08.052.
       Full Text  Link to Item
    • Charlton, Michael, Edward Gane, Michael P. Manns, Robert S. Brown, Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, et al. “Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation..” Gastroenterology 148, no. 1 (January 2015): 108–17. https://doi.org/10.1053/j.gastro.2014.10.001.
       Full Text  Link to Item
    • Muir, Andrew J., Sanjeev Arora, Gregory Everson, Robert Flisiak, Jacob George, Reem Ghalib, Stuart C. Gordon, et al. “A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection..” J Hepatol 61, no. 6 (December 2014): 1238–46. https://doi.org/10.1016/j.jhep.2014.07.022.
       Full Text  Link to Item
    • Muir, Andrew J. “Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care..” Top Antivir Med 22, no. 4 (September 2014): 685–89.
       Link to Item
    • Clark, Paul J., Alexander J. Thompson, Keyur Patel, Andrew J. Muir, and Michael L. Volk. “Trends in hepatitis C treatment uptake in the United States..” Hepatology 60, no. 2 (August 2014): 768–69. https://doi.org/10.1002/hep.27213.
       Full Text  Link to Item
    • Afdhal, Nezam, Stefan Zeuzem, Paul Kwo, Mario Chojkier, Norman Gitlin, Massimo Puoti, Manuel Romero-Gomez, et al. “Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection..” N Engl J Med 370, no. 20 (May 15, 2014): 1889–98. https://doi.org/10.1056/NEJMoa1402454.
       Full Text  Link to Item
    • Kowdley, Kris V., Stuart C. Gordon, K Rajender Reddy, Lorenzo Rossaro, David E. Bernstein, Eric Lawitz, Mitchell L. Shiffman, et al. “Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis..” N Engl J Med 370, no. 20 (May 15, 2014): 1879–88. https://doi.org/10.1056/NEJMoa1402355.
       Full Text  Link to Item
    • Muir, Andrew J. “The rapid evolution of treatment strategies for hepatitis C..” Am J Gastroenterol 109, no. 5 (May 2014): 628–35. https://doi.org/10.1038/ajg.2014.66.
       Full Text  Link to Item
    • Afdhal, Nezam, K Rajender Reddy, David R. Nelson, Eric Lawitz, Stuart C. Gordon, Eugene Schiff, Ronald Nahass, et al. “Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection..” N Engl J Med 370, no. 16 (April 17, 2014): 1483–93. https://doi.org/10.1056/NEJMoa1316366.
       Full Text  Link to Item
    • Melia, Michael T., Norbert Bräu, Fred Poordad, Eric J. Lawitz, Mitchell L. Shiffman, John G. McHutchison, Andrew J. Muir, et al. “Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study..” Clin Infect Dis 58, no. 7 (April 2014): 960–69. https://doi.org/10.1093/cid/ciu009.
       Full Text  Link to Item
    • Vierling, John M., Mitchell Davis, Steven Flamm, Stuart C. Gordon, Eric Lawitz, Eric M. Yoshida, Joseph Galati, et al. “Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response..” J Hepatol 60, no. 4 (April 2014): 748–56. https://doi.org/10.1016/j.jhep.2013.12.013.
       Full Text  Link to Item
    • Muir, A. J., L. Gong, S. G. Johnson, M. T. M. Lee, M. S. Williams, T. E. Klein, K. E. Caudle, D. R. Nelson, and D. R. Clinical Pharmacogenetics Implementation Consortium (CPIC). “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens..” Clin Pharmacol Ther 95, no. 2 (February 2014): 141–46. https://doi.org/10.1038/clpt.2013.203.
       Full Text  Link to Item
    • Thompson, Alex, Scott Devine, Mike Kattan, and Andrew Muir. “Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin..” Plos One 9, no. 8 (2014). https://doi.org/10.1371/journal.pone.0103370.
       Full Text  Link to Item
    • Clark, P. J., A. Aghemo, E. Degasperi, E. Galmozzi, T. J. Urban, D. M. Vock, K. Patel, et al. “Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy..” J Viral Hepat 20, no. 12 (December 2013): 858–66. https://doi.org/10.1111/jvh.12113.
       Full Text  Link to Item
    • Afdhal, N. H., S. Zeuzem, R. T. Schooley, D. L. Thomas, J. W. Ward, A. H. Litwin, H. Razavi, et al. “The new paradigm of hepatitis C therapy: integration of oral therapies into best practices..” J Viral Hepat 20, no. 11 (November 2013): 745–60. https://doi.org/10.1111/jvh.12173.
       Full Text  Link to Item
    • Jou, Janice H., Mark S. Sulkowski, Stephanie Noviello, Jianmin Long, Lisa D. Pedicone, John G. McHutchison, and Andrew J. Muir. “Analysis of site performance in academic-based and community-based centers in the IDEAL Study..” J Clin Gastroenterol 47, no. 10 (November 2013): e91–95. https://doi.org/10.1097/MCG.0b013e318294baa4.
       Full Text  Link to Item
    • Lawitz, Eric, Jay P. Lalezari, Tarek Hassanein, Kris V. Kowdley, Fred F. Poordad, Aasim M. Sheikh, Nezam H. Afdhal, et al. “Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial..” Lancet Infect Dis 13, no. 5 (May 2013): 401–8. https://doi.org/10.1016/S1473-3099(13)70033-1.
       Full Text  Link to Item
    • Luke, Frank E., Brian C. Allen, Sara T. Moshiri, Lisa M. Ho, Christopher M. Massey, Sandra S. Stinnett, Andrew J. Muir, and Tracy A. Jaffe. “Multiphase multi-detector row computed tomography in the setting of chronic liver disease and orthotopic liver transplantation: can a series be eliminated in order to reduce radiation dose?.” J Comput Assist Tomogr 37, no. 3 (May 2013): 408–14. https://doi.org/10.1097/RCT.0b013e3182838680.
       Full Text  Link to Item
    • Northup, Patrick G., Curtis K. Argo, Andrew J. Muir, Arthur J. Decross, Walter J. Coyle, and Amy S. Oxentenko. “Procedural competency of gastroenterology trainees: from apprenticeship to milestones..” Gastroenterology 144, no. 4 (April 2013): 677–80. https://doi.org/10.1053/j.gastro.2013.02.020.
       Full Text  Link to Item
    • Aronsohn, Andrew, Andrew J. Muir, Tracy Swan, and Donald Jensen. “Is the HCV pipeline heading in the right direction?.” Gastroenterology 144, no. 3 (March 2013): 482–85. https://doi.org/10.1053/j.gastro.2013.01.018.
       Full Text  Link to Item
    • Muir, Andrew J. “IL28B in the era of direct-acting antivirals for hepatitis C..” J Clin Gastroenterol 47, no. 3 (March 2013): 222–27. https://doi.org/10.1097/MCG.0b013e3182680221.
       Full Text  Link to Item
    • Bailey, Rahn K., Andrew J. Muir, Charles D. Howell, Cedric Bright, Philip R. Roane, Eyasu Teshale, Courtney M. Johnson, et al. “The hepatitis C crisis in the African American Community: findings and recommendations..” J Natl Med Assoc 105, no. 2 (2013): 108–11. https://doi.org/10.1016/s0027-9684(15)30114-0.
       Full Text  Link to Item
    • Jou, J. H., and A. J. Muir. “Hepatitis C.” Annals of Internal Medicine 157, no. 11 (December 10, 2012): 1–16.
    • Jou, Janice H., and Andrew J. Muir. “In the clinic. Hepatitis C..” Ann Intern Med 157, no. 11 (December 4, 2012). https://doi.org/10.7326/0003-4819-157-11-201212040-01006.
       Full Text  Link to Item
    • Muir, Andrew J. “Approach to the treatment-naïve patient with HCV genotype 1 infection..” Infect Dis Clin North Am 26, no. 4 (December 2012): 893–901. https://doi.org/10.1016/j.idc.2012.08.012.
       Full Text  Link to Item
    • Clark, P. J., A. J. Thompson, Q. Zhu, D. M. Vock, M. Zhu, K. Patel, S. A. Harrison, et al. “Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479)).” Digestive Diseases and Sciences 57, no. 9 (September 1, 2012). https://doi.org/10.1007/s10620-012-2309-y.
       Full Text
    • Gellad, Ziad F., Andrew J. Muir, John G. McHutchison, William Sievert, Ala I. Sharara, Kimberly A. Brown, Robert Flisiak, et al. “Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response..” Value Health 15, no. 6 (September 2012): 876–86. https://doi.org/10.1016/j.jval.2012.06.010.
       Full Text  Link to Item
    • Norton, Brianna L., Lawrence Park, Leah J. McGrath, Rae Jean Proeschold Bell, Andrew J. Muir, and Susanna Naggie. “Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection..” Aids Patient Care Stds 26, no. 9 (September 2012): 541–45. https://doi.org/10.1089/apc.2012.0170.
       Full Text  Link to Item
    • Clark, Paul J., Alexander J. Thompson, Qianqian Zhu, David M. Vock, Mingfu Zhu, Keyur Patel, Stephen A. Harrison, et al. “The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection..” Dig Dis Sci 57, no. 8 (August 2012): 2213–21. https://doi.org/10.1007/s10620-012-2171-y.
       Full Text  Link to Item
    • Naggie, Susanna, Anu Osinusi, Antonios Katsounas, Richard Lempicki, Eva Herrmann, Alexander J. Thompson, Paul J. Clark, et al. “Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response..” Hepatology 56, no. 2 (August 2012): 444–54. https://doi.org/10.1002/hep.25647.
       Full Text  Link to Item
    • Clark, Paul J., Alexander J. Thompson, David M. Vock, Lisa E. Kratz, Adviye A. Tolun, Andrew J. Muir, John G. McHutchison, et al. “Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner..” Hepatology 56, no. 1 (July 2012): 49–56. https://doi.org/10.1002/hep.25631.
       Full Text  Link to Item
    • Clark, Paul J., and Andrew J. Muir. “Lost in translation? IL28B's discovery and the journey back to the patient..” Hepatology 56, no. 1 (July 2012): 5–8. https://doi.org/10.1002/hep.25796.
       Full Text  Link to Item
    • Clark, Paul J., and Andrew J. Muir. “Overcoming barriers to care for hepatitis C..” N Engl J Med 366, no. 26 (June 28, 2012): 2436–38. https://doi.org/10.1056/NEJMp1202608.
       Full Text  Link to Item
    • Clark, P. J., A. J. Thompson, M. Zhu, D. M. Vock, Q. Zhu, D. Ge, K. Patel, et al. “Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response..” J Viral Hepat 19, no. 5 (May 2012): 332–40. https://doi.org/10.1111/j.1365-2893.2011.01553.x.
       Full Text  Link to Item
    • Muir, Andrew J. “Surgical clearance for the patient with chronic liver disease..” Clin Liver Dis 16, no. 2 (May 2012): 421–33. https://doi.org/10.1016/j.cld.2012.03.008.
       Full Text  Link to Item
    • Proeschold-Bell, Rae Jean, Ashwin A. Patkar, Susanna Naggie, Lesleyjill Coward, Paolo Mannelli, Jia Yao, Patricia Bixby, and Andrew J. Muir. “An integrated alcohol abuse and medical treatment model for patients with hepatitis C..” Dig Dis Sci 57, no. 4 (April 2012): 1083–91. https://doi.org/10.1007/s10620-011-1976-4.
       Full Text  Open Access Copy  Link to Item
    • Jazwinski, A., and A. Muir. “IL28B: Implications for clinical practice.” Current Hepatitis Reports 11, no. 1 (March 1, 2012): 15–22. https://doi.org/10.1007/s11901-011-0118-y.
       Full Text
    • Thompson, A. J., P. J. Clark, A. J. Muir, and M. S. Sulkowski. “Reply to "iL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?".” Journal of Hepatology 56, no. 3 (March 1, 2012): 742–43. https://doi.org/10.1016/j.jhep.2011.08.011.
       Full Text
    • Thompson, Alexander J., Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, et al. “Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients..” J Hepatol 56, no. 2 (February 2012): 313–19. https://doi.org/10.1016/j.jhep.2011.04.021.
       Full Text  Link to Item
    • Gellad, Ziad F., Shelby D. Reed, and Andrew J. Muir. “Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C..” Antivir Ther 17, no. 6 Pt B (2012): 1189–99. https://doi.org/10.3851/IMP2430.
       Full Text  Link to Item
    • Vock, David M., Marie Davidian, Anastasios A. Tsiatis, and Andrew J. Muir. “Mixed model analysis of censored longitudinal data with flexible random-effects density..” Biostatistics 13, no. 1 (January 2012): 61–73. https://doi.org/10.1093/biostatistics/kxr026.
       Full Text  Link to Item
    • Muir, Andrew J. “Telaprevir for the treatment of chronic hepatitis C infection..” Expert Rev Anti Infect Ther 9, no. 12 (December 2011): 1105–14. https://doi.org/10.1586/eri.11.133.
       Full Text  Link to Item
    • Tillmann, Hans L., Keyur Patel, Andrew J. Muir, Cynthia D. Guy, Josephine H. Li, Xiang Qian Lao, Alexander Thompson, et al. “Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C..” J Hepatol 55, no. 6 (December 2011): 1195–1200. https://doi.org/10.1016/j.jhep.2011.03.015.
       Full Text  Link to Item
    • Muir, A. J. “HCV and Racial Differences,” November 3, 2011, 185–89. https://doi.org/10.1002/9781444346343.ch23.
       Full Text
    • Muir, Andrew J., Fred F. Poordad, John G. McHutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E Jenny Heathcote, et al. “Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response..” Hepatology 54, no. 5 (November 2011): 1538–46. https://doi.org/10.1002/hep.24549.
       Full Text  Link to Item
    • Proeschold-Bell, Rae Jean, Bettina Hoeppner, Baishakhi Taylor, Sarah Cohen, Rachel Blouin, Beth Stringfield, and Andrew J. Muir. “An interrupted time series evaluation of a hepatitis C intervention for persons with HIV..” Aids Behav 15, no. 8 (November 2011): 1721–31. https://doi.org/10.1007/s10461-010-9870-1.
       Full Text  Link to Item
    • Jazwinski, Alison B., and Andrew J. Muir. “Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals..” Gastroenterol Clin North Am 40, no. 3 (September 2011): 481–94. https://doi.org/10.1016/j.gtc.2011.06.005.
       Full Text  Link to Item
    • Melia, Michael T., Andrew J. Muir, Jonathan McCone, Mitchell L. Shiffman, John W. King, Steven K. Herrine, Greg W. Galler, et al. “Racial differences in hepatitis C treatment eligibility..” Hepatology 54, no. 1 (July 2011): 70–78. https://doi.org/10.1002/hep.24358.
       Full Text  Link to Item
    • Jacobson, Ira M., John G. McHutchison, Geoffrey Dusheiko, Adrian M. Di Bisceglie, K Rajender Reddy, Natalie H. Bzowej, Patrick Marcellin, et al. “Telaprevir for previously untreated chronic hepatitis C virus infection..” N Engl J Med 364, no. 25 (June 23, 2011): 2405–16. https://doi.org/10.1056/NEJMoa1012912.
       Full Text  Link to Item
    • Muir, Andrew J. “The protease inhibitor era: an opportunity to improve the quality of care..” Dig Dis Sci 56, no. 5 (May 2011): 1252–54. https://doi.org/10.1007/s10620-011-1674-2.
       Full Text  Link to Item
    • Muir, A. J., K. -. Q. Hu, S. C. Gordon, K. Koury, N. Boparai, S. Noviello, J. K. Albrecht, M. S. Sulkowski, and J. McCone. “Hepatitis C treatment among racial and ethnic groups in the IDEAL trial..” J Viral Hepat 18, no. 4 (April 2011): e134–43. https://doi.org/10.1111/j.1365-2893.2010.01402.x.
       Full Text  Link to Item
    • Poordad, F., J. McCone, B. R. Bacon, S. Bruno, M. P. Manns, M. S. Sulkowski, I. M. Jacobson, et al. “Boceprevir for untreated chronic HCV genotype 1 infection.” New England Journal of Medicine 364, no. 13 (March 31, 2011): 1195–1206. https://doi.org/10.1056/NEJMoa1010494.
       Full Text
    • Clark, P. J., A. J. V. Thompson, and A. J. Muir. “IL28B polymorphisms and treatment of hepatitis C.” Current Hepatitis Reports 10, no. 1 (March 1, 2011): 70–78. https://doi.org/10.1007/s11901-010-0061-3.
       Full Text
    • Jazwinski, Alison B., and Andrew J. Muir. “Direct-acting antiviral medications for chronic hepatitis C virus infection..” Gastroenterol Hepatol (N Y) 7, no. 3 (March 2011): 154–62.
       Link to Item
    • Thompson, Alexander J., Rosanna Santoro, Valeria Piazzolla, Paul J. Clark, Susanna Naggie, Hans L. Tillmann, Keyur Patel, et al. “Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR..” Hepatology 53, no. 2 (February 2011): 389–95. https://doi.org/10.1002/hep.24068.
       Full Text  Link to Item
    • Jou, Janice H., Po-Hung Chen, Alison Jazwinski, Iliana Bouneva, Alastair D. Smith, and Andrew J. Muir. “Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center..” Dig Dis Sci 55, no. 12 (December 2010): 3591–96. https://doi.org/10.1007/s10620-010-1366-3.
       Full Text  Link to Item
    • Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, et al. “Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype..” Hepatology 52, no. 6 (December 2010): 2243–44. https://doi.org/10.1002/hep.23826.
       Full Text  Link to Item
    • Bailey, Donald E., Julie Barroso, Andrew J. Muir, Richard Sloane, Jacqui Richmond, John McHutchison, Keyur Patel, Lawrence Landerman, and Merle H. Mishel. “Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue..” Res Nurs Health 33, no. 5 (October 2010): 465–73. https://doi.org/10.1002/nur.20397.
       Full Text  Link to Item
    • Poordad, Fred, Eric Lawitz, Mitchell L. Shiffman, Tarek Hassanein, Andrew J. Muir, Bruce R. Bacon, Jamie Heise, Deanine Halliman, Eric Chun, and Janet Hammond. “Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C..” Hepatology 52, no. 4 (October 2010): 1208–15. https://doi.org/10.1002/hep.23827.
       Full Text  Link to Item
    • Thompson, Alexander J., Jacques Fellay, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Dongliang Ge, Thomas J. Urban, et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction..” Gastroenterology 139, no. 4 (October 2010): 1181–89. https://doi.org/10.1053/j.gastro.2010.06.016.
       Full Text  Link to Item
    • Zeuzem, Stefan, Mark S. Sulkowski, Eric J. Lawitz, Vinod K. Rustgi, Maribel Rodriguez-Torres, Bruce R. Bacon, Mircea Grigorescu, et al. “Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1..” Gastroenterology 139, no. 4 (October 2010): 1257–66. https://doi.org/10.1053/j.gastro.2010.06.066.
       Full Text  Link to Item
    • Muir, Andrew J., Mitchell L. Shiffman, Atif Zaman, Boris Yoffe, Andrew de la Torre, Steven Flamm, Stuart C. Gordon, et al. “Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection..” Hepatology 52, no. 3 (September 2010): 822–32. https://doi.org/10.1002/hep.23743.
       Full Text  Link to Item
    • Anderson, Albert M., Marina B. Mosunjac, Melody P. Palmore, Melissa K. Osborn, and Andrew J. Muir. “Development of fatal acute liver failure in HIV-HBV coinfected patients..” World J Gastroenterol 16, no. 32 (August 28, 2010): 4107–11. https://doi.org/10.3748/wjg.v16.i32.4107.
       Full Text  Link to Item
    • Castor, J. M., R. K. Wood, A. J. Muir, S. M. Palmer, and R. A. Shimpi. “Gastroesophageal reflux and altered motility in lung transplant rejection..” Neurogastroenterol Motil 22, no. 8 (August 2010): 841–50. https://doi.org/10.1111/j.1365-2982.2010.01522.x.
       Full Text  Link to Item
    • Richmond, Jacqueline A., Donald E. Bailey, Keyur Patel, Janet A. Jezsik, Andrew Muir, Jr-Rung Lin, Shein-Chung Chow, Diane Uzarski, and John G. McHutchison. “The use of complementary and alternative medicine by patients with chronic hepatitis C..” Complement Ther Clin Pract 16, no. 3 (August 2010): 124–31. https://doi.org/10.1016/j.ctcp.2009.10.004.
       Full Text  Link to Item
    • Proeschold-Bell, Rae Jean, Rachel Blouin, Susan Reif, Arit Amana, Benjamin J. Rowland, Frank Lombard, Beth Stringfield, and Andrew J. Muir. “Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV..” South Med J 103, no. 7 (July 2010): 635–41. https://doi.org/10.1097/SMJ.0b013e3181e1dde1.
       Full Text  Link to Item
    • Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Dongliang Ge, Jacques Fellay, Kevin V. Shianna, Thomas Urban, et al. “Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus..” Gastroenterology 139, no. 1 (July 2010): 120-9.e18. https://doi.org/10.1053/j.gastro.2010.04.013.
       Full Text  Link to Item
    • Li, Josephine H., Xiang Qian Lao, Hans L. Tillmann, Jennifer Rowell, Keyur Patel, Alexander Thompson, Sunil Suchindran, et al. “Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection..” Hepatology 51, no. 6 (June 2010): 1904–11. https://doi.org/10.1002/hep.23592.
       Full Text  Link to Item
    • McCarthy, Jeanette J., Josephine H. Li, Alexander Thompson, Sunil Suchindran, Xiang Qian Lao, Keyur Patel, Hans L. Tillmann, Andrew J. Muir, and John G. McHutchison. “Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin..” Gastroenterology 138, no. 7 (June 2010): 2307–14. https://doi.org/10.1053/j.gastro.2010.02.009.
       Full Text  Link to Item
    • Castellino, Sharon, Andrew Muir, Ami Shah, Sheila Shope, Kevin McMullen, Kathy Ruble, Ashley Barber, Andrew Davidoff, and Melissa M. Hudson. “Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group..” Pediatr Blood Cancer 54, no. 5 (May 2010): 663–69. https://doi.org/10.1002/pbc.22265.
       Full Text  Link to Item
    • Muir, A. J. “Telaprevir in the treatment of patients with genotype 1 hepatitis C.” Gastroenterology and Hepatology 6, no. 5 (May 1, 2010): 303–5.
    • Richmond, Jacqueline A., Donald E. Bailey, John G. McHutchison, and Andrew J. Muir. “The use of mind-body medicine and prayer among adult patients with chronic hepatitis C..” Gastroenterol Nurs 33, no. 3 (May 2010): 210–16. https://doi.org/10.1097/SGA.0b013e3181e01a7b.
       Full Text  Link to Item
    • McHutchison, John G., Michael P. Manns, Andrew J. Muir, Norah A. Terrault, Ira M. Jacobson, Nezam H. Afdhal, E Jenny Heathcote, et al. “Telaprevir for previously treated chronic HCV infection..” N Engl J Med 362, no. 14 (April 8, 2010): 1292–1303. https://doi.org/10.1056/NEJMoa0908014.
       Full Text  Link to Item
    • Fellay, Jacques, Alexander J. Thompson, Dongliang Ge, Curtis E. Gumbs, Thomas J. Urban, Kevin V. Shianna, Latasha D. Little, et al. “ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C..” Nature 464, no. 7287 (March 18, 2010): 405–8. https://doi.org/10.1038/nature08825.
       Full Text  Link to Item
    • Hantouche, E., S. Kirkiacharian, J. G. McHutchison, M. P. Mann, A. J. Muir, E. Trudel, C. W. Bourque, et al. “Editorial: Accreditation: The Revue Francophone des Laboratoires seeks dialogue.” Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010). https://doi.org/10.1016/S1773-035X(10)70525-6.
       Full Text
    • Naudin, C., E. Hantouche, S. Kirkiacharian, J. G. McHutchison, M. P. Mann, A. J. Muir, E. Trudel, et al. “Accreditation: What you want to know - Abusus non tollit usum. An interview with Drs. Anne-Marie Gallot and Michel Ballereau.” Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010): 8–13. https://doi.org/10.1016/S1773-035X(10)70526-8.
       Full Text
    • Naudin, C., E. Hantouche, S. Kirkiacharian, J. G. McHutchison, M. P. Mann, A. J. Muir, E. Trudel, et al. “Ortho Clinical Diagnostics: Scientific knowledge influences our way of life.” Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010): 14–16. https://doi.org/10.1016/S1773-035X(10)70527-X.
       Full Text
    • Ge, Dongliang, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, et al. “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance..” Nature 461, no. 7262 (September 17, 2009): 399–401. https://doi.org/10.1038/nature08309.
       Full Text  Link to Item
    • McHutchison, John G., Eric J. Lawitz, Mitchell L. Shiffman, Andrew J. Muir, Greg W. Galler, Jonathan McCone, Lisa M. Nyberg, et al. “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection..” N Engl J Med 361, no. 6 (August 6, 2009): 580–93. https://doi.org/10.1056/NEJMoa0808010.
       Full Text  Link to Item
    • McHutchison, John G., Gregory T. Everson, Stuart C. Gordon, Ira M. Jacobson, Mark Sulkowski, Robert Kauffman, Lindsay McNair, John Alam, Andrew J. Muir, and Andrew J. PROVE1 Study Team. “Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection..” N Engl J Med 360, no. 18 (April 30, 2009): 1827–38. https://doi.org/10.1056/NEJMoa0806104.
       Full Text  Link to Item
    • Bailey, Donald E., Lawrence Landerman, Julie Barroso, Patricia Bixby, Merle H. Mishel, Andrew J. Muir, Lisa Strickland, and Elizabeth Clipp. “Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C..” Psychosomatics 50, no. 2 (March 2009): 138–46. https://doi.org/10.1176/appi.psy.50.2.138.
       Full Text  Link to Item
    • Nelson, David R., Vinod Rustgi, Vijayan Balan, Mark S. Sulkowski, Gary L. Davis, Andrew J. Muir, Louis R. Lambiase, et al. “Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C..” Clin Gastroenterol Hepatol 7, no. 2 (February 2009): 212–18. https://doi.org/10.1016/j.cgh.2008.10.035.
       Full Text  Link to Item
    • Moylan, Cynthia A., Carla W. Brady, Jeffrey L. Johnson, Alastair D. Smith, Janet E. Tuttle-Newhall, and Andrew J. Muir. “Disparities in liver transplantation before and after introduction of the MELD score..” Jama 300, no. 20 (November 26, 2008): 2371–78. https://doi.org/10.1001/jama.2008.720.
       Full Text  Link to Item
    • Canlas, Karen R., Brian M. Dobozi, Sauyu Lin, Alastair D. Smith, Don C. Rockey, Andrew J. Muir, Naurang M. Agrawal, Martin H. Poleski, Keyur Patel, and John G. McHutchison. “Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia..” J Clin Gastroenterol 42, no. 7 (August 2008): 844–48. https://doi.org/10.1097/MCG.0b013e318038d312.
       Full Text  Link to Item
    • Lawitz, Eric, Maribel Rodriguez-Torres, Andrew J. Muir, Tara L. Kieffer, Lindsay McNair, Ariya Khunvichai, and John G. McHutchison. “Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients..” J Hepatol 49, no. 2 (August 2008): 163–69. https://doi.org/10.1016/j.jhep.2008.03.027.
       Full Text  Link to Item
    • Jou, Janice H., and Andrew J. Muir. “In the clinic. Hepatitis C..” Ann Intern Med 148, no. 11 (June 3, 2008). https://doi.org/10.7326/0003-4819-148-11-200806030-01006.
       Full Text  Link to Item
    • Brady, Carla W., Alastair D. Smith, Karen M. Stechuchak, Cynthia J. Coffman, Janet E. Tuttle-Newhall, Dawn Provenzale, and Andrew J. Muir. “Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era..” Liver Transpl 14, no. 2 (February 2008): 228–34. https://doi.org/10.1002/lt.21346.
       Full Text  Link to Item
    • Weegink, C. J., N. Forestier, P. L. Jansen, S. Zeuzem, H. W. Reesink, I. M. Jacobson, G. T. Everson, et al. “Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection.” Gastroenterology and Hepatology 4, no. 2 SUPPL. 6 (February 1, 2008): 5–13.
    • Muir, A. J. “Immunosuppressive Medications,” December 13, 2007, 503–21. https://doi.org/10.1002/9780470751541.ch29.
       Full Text
    • Gellad, Z. F., B. D. Alexander, J. K. Liu, B. C. Griffith, A. M. Meyer, J. L. Johnson, and A. J. Muir. “Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients..” Transpl Infect Dis 9, no. 4 (December 2007): 276–80. https://doi.org/10.1111/j.1399-3062.2007.00255.x.
       Full Text  Link to Item
    • McHutchison, John G., Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz, Mitchell Shiffman, Nezam H. Afdhal, Ira M. Jacobson, et al. “Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus..” Hepatology 46, no. 5 (November 2007): 1341–49. https://doi.org/10.1002/hep.21773.
       Full Text  Link to Item
    • Branagan, N., and A. J. Muir. “Hepatitis C - Current advances in therapy.” Practical Gastroenterology 31, no. 8 (August 1, 2007): 20–29.
    • Muir, Andrew J., and John G. McHutchison. “Growth factors during HCV therapy may be "cost-effective", but are they "effective"?.” Hepatology 44, no. 6 (December 2006): 1400–1403. https://doi.org/10.1002/hep.21426.
       Full Text  Link to Item
    • Ramamurthy, Meera, and Andrew J. Muir. “Treatment of hepatitis C in special populations..” Clin Liver Dis 10, no. 4 (November 2006): 851–65. https://doi.org/10.1016/j.cld.2006.08.001.
       Full Text  Link to Item
    • Scales, Charles D., Steve Fein, Andrew J. Muir, and Don C. Rockey. “Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission..” J Clin Gastroenterol 40, no. 10 (November 2006): 913–18. https://doi.org/10.1097/01.mcg.0000225674.14594.9f.
       Full Text  Link to Item
    • Heneghan, Michael A., Michael L. Allan, Jeffrey D. Bornstein, Andrew J. Muir, and David A. Tendler. “Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis..” J Hepatol 45, no. 4 (October 2006): 584–91. https://doi.org/10.1016/j.jhep.2006.05.011.
       Full Text  Link to Item
    • Brady, C. W., and A. J. Muir. “The impact of race and ethnicity on the treatment of hepatitis C disease.” Current Hepatitis Reports 5, no. 3 (August 1, 2006): 79–85. https://doi.org/10.1007/s11901-006-0009-9.
       Full Text
    • Muir, A. J., P. B. Sylvestre, and D. C. Rockey. “Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection..” J Viral Hepat 13, no. 5 (May 2006): 322–28. https://doi.org/10.1111/j.1365-2893.2005.00689.x.
       Full Text  Link to Item
    • Patel, Keyur, Andrew J. Muir, and John G. McHutchison. “Diagnosis and treatment of chronic hepatitis C infection..” Bmj 332, no. 7548 (April 29, 2006): 1013–17. https://doi.org/10.1136/bmj.332.7548.1013.
       Full Text  Link to Item
    • Muir, Andrew J. “HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?.” Nat Clin Pract Gastroenterol Hepatol 2, no. 12 (December 2005): 568–69. https://doi.org/10.1038/ncpgasthep0337.
       Full Text  Link to Item
    • Moylan, Cynthia A., and Andrew J. Muir. “Treatment of hepatitis C in special populations..” Clin Liver Dis 9, no. 4 (November 2005): 567–v. https://doi.org/10.1016/j.cld.2005.07.005.
       Full Text  Link to Item
    • Brady, Carla W., and Andrew J. Muir. “HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis..” Hepatology 42, no. 2 (August 2005): 496–97. https://doi.org/10.1002/hep.20777.
       Full Text  Link to Item
    • Condron, Steven L., Michael A. Heneghan, Keyur Patel, Anouk Dev, John G. McHutchison, and Andrew J. Muir. “Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection..” Transplantation 80, no. 1 (July 15, 2005): 145–48. https://doi.org/10.1097/01.tp.0000164291.35925.7a.
       Full Text  Link to Item
    • Smith, Alastair D., Diane Bai, Carlos E. Marroquin, Janet E. Tuttle-Newhall, Dev M. Desai, Bradley H. Collins, Andrew Muir, Paul C. Kuo, John McHutchison, and Don C. Rockey. “Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus..” Clin Transplant 19, no. 2 (April 2005): 250–54. https://doi.org/10.1111/j.1399-0012.2005.00332.x.
       Full Text  Link to Item
    • Balan, Vijayan, David Schwartz, George Y. Wu, Andrew J. Muir, Reem Ghalib, John Jackson, Emmet B. Keeffe, et al. “Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin..” Am J Gastroenterol 100, no. 2 (February 2005): 299–307. https://doi.org/10.1111/j.1572-0241.2005.40757.x.
       Full Text  Link to Item
    • Zekry, Amany, Keyur Patel, Andrew Muir, and John G. McHutchison. “Tinkering and tailoring with HCV therapy: can we get away with less?.” Hepatology 40, no. 6 (December 2004): 1249–51. https://doi.org/10.1002/hep.20513.
       Full Text  Link to Item
    • Moriguchi, Hisashi, and Chifumi Sato. “Treatment of chronic hepatitis C in blacks and non-Hispanic whites..” N Engl J Med 351, no. 8 (August 19, 2004): 831–32.
       Link to Item
    • Muir, Andrew J., Jeffrey D. Bornstein, Paul G. Killenberg, and Paul G. Atlantic Coast Hepatitis Treatment Group. “Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites..” N Engl J Med 350, no. 22 (May 27, 2004): 2265–71. https://doi.org/10.1056/NEJMoa032502.
       Full Text  Link to Item
    • Dev, Anouk, Keyur Patel, Andrew Muir, and John G. McHutchison. “Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions..” Am J Gastroenterol 98, no. 11 (November 2003): 2344–47. https://doi.org/10.1111/j.1572-0241.2003.08696.x.
       Full Text  Link to Item
    • Patel, Keyur, Anouk Dev, Andrew J. Muir, and John G. McHutchison. “Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?.” Hepatology 38, no. 1 (July 2003): 21–24. https://doi.org/10.1053/jhep.2003.50326.
       Full Text  Link to Item
    • Schmidt, T. D., and A. J. Muir. “A case of electrical storm in a liver transplant patient..” Transplant Proc 35, no. 4 (June 2003): 1437–38. https://doi.org/10.1016/s0041-1345(03)00462-7.
       Full Text  Link to Item
    • Heneghan, Michael A., J Elizabeth Tuttle-Newhall, Paul V. Suhocki, Andrew J. Muir, Michael Morse, Jeffrey D. Bornstein, Pamela B. Sylvestre, Bradley Collins, Paul C. Kuo, and Don C. Rockey. “De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant..” Am J Transplant 3, no. 5 (May 2003): 634–38.
       Link to Item
    • Patel, K., A. Muir, J. G. McHutchison, and H. M. Patton. “A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats..” Am J Gastroenterol 98, no. 5 (May 2003): 952–55. https://doi.org/10.1111/j.1572-0241.2003.07422.x.
       Full Text  Link to Item
    • Patel, Keyur, Andrew J. Muir, and John G. McHutchison. “Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients..” Hepatology 37, no. 5 (May 2003). https://doi.org/10.1053/jhep.2003.50159.
       Full Text  Link to Item
    • Thabut, Dominique, Marion Simon, Robert P. Myers, Djamila Messous, Vincent Thibault, Françoise Imbert-Bismut, and Thierry Poynard. “Noninvasive prediction of fibrosis in patients with chronic hepatitis C..” Hepatology 37, no. 5 (May 2003): 1220–21. https://doi.org/10.1053/jhep.2003.50109.
       Full Text  Link to Item
    • Muir, Andrew J., Linda L. Sanders, Michael A. Heneghan, Paul C. Kuo, William E. Wilkinson, and Dawn Provenzale. “An examination of factors predicting prioritization for liver transplantation..” Liver Transpl 8, no. 10 (October 2002): 957–61. https://doi.org/10.1053/jlts.2002.35545.
       Full Text  Link to Item
    • Muir, Andrew J., and James F. Trotter. “A survey of current liver biopsy practice patterns..” J Clin Gastroenterol 35, no. 1 (July 2002): 86–88. https://doi.org/10.1097/00004836-200207000-00018.
       Full Text  Link to Item
    • Serpe, Marcelo D., Alan J. Muir, and Azeddine Driouich. “Immunolocalization of beta-D-glucans, pectins, and arabinogalactan-proteins during intrusive growth and elongation of nonarticulated laticifers in Asclepias speciosa Torr..” Planta 215, no. 3 (July 2002): 357–70. https://doi.org/10.1007/s00425-002-0756-y.
       Full Text  Link to Item
    • Patel, Robin, and Jeffrey J. Germer. “Treatment of acute hepatitis C with interferon alfa-2b..” N Engl J Med 346, no. 14 (April 4, 2002): 1091–92. https://doi.org/10.1056/NEJM200204043461414.
       Full Text  Link to Item
    • Muir, Andrew J., and Don C. Rockey. “Acute HCV: the early bird catches the virus..” Gastroenterology 122, no. 4 (April 2002): 1176–77. https://doi.org/10.1016/s0016-5085(02)80196-2.
       Full Text  Link to Item
    • Muir, Andrew J., and Dawn Provenzale. “A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection..” J Clin Gastroenterol 34, no. 3 (March 2002): 268–71. https://doi.org/10.1097/00004836-200203000-00015.
       Full Text  Link to Item
    • Muir, A. J., L. J. Edwards, L. L. Sanders, R. R. Bollinger, M. J. Koruda, D. R. Bachwich, and D. Provenzale. “A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis..” Am J Gastroenterol 96, no. 5 (May 2001): 1480–85. https://doi.org/10.1111/j.1572-0241.2001.03801.x.
       Full Text  Link to Item
    • Muir, A. J., L. L. Sanders, W. E. Wilkinson, and K. Schmader. “Reducing medication regimen complexity: a controlled trial..” J Gen Intern Med 16, no. 2 (February 2001): 77–82. https://doi.org/10.1046/j.1525-1497.2001.016002077.x.
       Full Text  Link to Item
    • Serpe, M. D., A. J. Muir, and A. M. Keidel. “Localization of cell wall polysaccharides in nonarticulated laticifers of Asclepias speciosa Torr..” Protoplasma 216, no. 3–4 (2001): 215–26.
       Link to Item
    • Muir, A. J. “The natural history of hepatitis C viral infection..” Semin Gastrointest Dis 11, no. 2 (April 2000): 54–61.
       Link to Item
    • Muir, Andrew J., Dawn Provenzale, and Jane E. Onken. “Fistulous complications in Crohn's disease: Impact on health related quality of life (HRQL) and resource utilization.” Gastroenterology 118, no. 4 (April 2000): A585–A585. https://doi.org/10.1016/s0016-5085(00)84477-7.
       Full Text
    • Palker, T. J., A. J. Muir, D. E. Spragion, H. F. Staats, A. Langlois, and D. C. Montefiori. “The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope..” Virology 224, no. 2 (October 15, 1996): 415–26. https://doi.org/10.1006/viro.1996.0548.
       Full Text  Link to Item
    • Palker, T. J., E. R. Riggs, D. E. Spragion, A. J. Muir, R. M. Scearce, R. R. Randall, M. W. McAdams, A. McKnight, P. R. Clapham, and R. A. Weiss. “Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins..” J Virol 66, no. 10 (October 1992): 5879–89.
       Link to Item
    • Muir, A. J., D. Bell, M. Jackson, J. J. Nicoll, and A. M. Millar. “The use of 111In-labelled autologous neutrophils in imaging myocardial infarction..” Nucl Med Commun 9, no. 10 (October 1988): 707–11. https://doi.org/10.1097/00006231-198810000-00006.
       Full Text  Link to Item

  • Book Sections

    • Jazwinski, A. B., and A. J. Muir. “The genetics of virologic response.” In Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future, 183–92, 2012. https://doi.org/10.1007/978-1-4614-1192-5_15.
       Full Text

  • Conference Papers

    • Helzberg, James H., Alice Parish, Donna Niedzwiecki, Charles Y. Kim, Julius M. Wilder, and Andrew J. Muir. “TIPS Outcomes According to Race and Ethnicity.” In American Journal of Gastroenterology, 113:S496–S496. NATURE PUBLISHING GROUP, 2018.
       Link to Item
    • Kappus, Matthew R., Kara Wegermann, Katie Charles, Yuval Patel, Gemini Janas, Erol Bozdogan, Alice Parish, Donna Niedzwiecki, Andrew Joseph Muir, and Mustafa Bashir. “Use of Skeletal Muscle Index As a Predictor of Waitlist Mortality in Patients with End-Stage Liver Disease.” In Hepatology, 68:658A-659A. WILEY, 2018.
       Link to Item
    • Muir, Andrew Joseph, Jia Yao, Julius Wilder, Christina Makarushka, Kelly Keefe, James Henry Helzberg, Paolo Mannelli, et al. “The Alcohol Use Disorders Identification Test Screening in Patients with Hepatitis C.” In Hepatology, 68:908A-908A. WILEY, 2018.
       Link to Item
    • Patel, Yuval, Jacqueline Henson, Julius Wilder, Matthew R. Kappus, Andrew S. Barbas, Cynthia A. Moylan, Donna Niedzwiecki, Andrew Joseph Muir, and Carl L. Berg. “The Impact of Advanced Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients.” In Hepatology, 68:683A-683A. WILEY, 2018.
       Link to Item
    • Younossi, Zobair M., Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, et al. “Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO..” In Hepatology, 68:155–65, 2018. https://doi.org/10.1002/hep.29664.
       Full Text  Link to Item
    • Wilder, Julius M., Jia Yao, Makarushka Christina, Donna Evon, Michael W. Fried, Susanna Naggie, Andrew J. Muir, and Rae Jean Proeschold-Bell. “ASSOCIATIONS OF ALCOHOL CONSUMPTION MOTIVES WITH DEPRESSION AND PAIN AMONG INDIVIDUALS WITH HEPATITIS C.” In Gastroenterology, 154:S1121–22. W B SAUNDERS CO-ELSEVIER INC, 2018.
       Link to Item
    • Harrison, Stephen A., Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, Reem Ghalib, Eric Lawitz, et al. “Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis.” In Hepatology, 66:1120A-1121A. WILEY, 2017.
       Link to Item
    • Muir, Andrew J., Mehdi Taghipour, Elmira Hassanzadeh, V Anik Sahni, Nisha Sainani, Dora Ding, Catherine Jia, et al. “A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC).” In Hepatology, 66:81A-81A. WILEY, 2017.
       Link to Item
    • Muir, Andrew J., Mehdi Taghipour, Elmira Hassanzadeh, V Anik Sahni, Nisha Sainani, Mitchell L. Shiffman, Dora Ding, et al. “Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial.” In Hepatology, 66:156A-156A. WILEY, 2017.
       Link to Item
    • Tempany-Afdhal, Clare, Mehdi Taghipour, Peter A. Behringer, Elmira Hassanzadeh, V Anik Sahni, Nisha Sainani, Dora Ding, et al. “Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance.” In Hepatology, 66:164A-165A. WILEY, 2017.
       Link to Item
    • Sanyal, Arun, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen H. Caldwell, Mitchell L. Shiffman, et al. “Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis.” In Gastroenterology, 152:S1055–S1055. Elsevier BV, 2017. https://doi.org/10.1016/s0016-5085(17)33563-1.
       Full Text
    • French, Dorothy, Erik G. Huntzicker, Zachary D. Goodman, Patrick R. Shea, Dora Ding, Raul E Aguilar Schall, Victoria Smith, et al. “Hepatic expression of lysyl oxidase-like-2 ( LOXL2) in primary sclerosing cholangitis (PSC).” In Hepatology, 64:194A-194A. WILEY, 2016.
       Link to Item
    • Henson, Jacqueline B., Julius M. Wilder, Yuval A. Patel, Jiayin Zheng, Shein-Chung Chow, Lindsay Y. King, and Andrew J. Muir. “Phenotypic Differences in Primary Sclerosing Cholangitis by Age Group.” In Hepatology, 64:185A-185A. WILEY, 2016.
       Link to Item
    • Muir, Andrew J., Maria Buti, Ronald Nahass, Kosh Agarwal, Edward J. Gane, Simone I. Strasser, Alessandra Mangia, et al. “Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens.” In Hepatology, 64:437A-438A. WILEY, 2016.
       Link to Item
    • Nitsche, Bruce, Sara Miller, and Andrew J. Muir. “Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer.” In Hepatology, 64:856A-857A. WILEY, 2016.
       Link to Item
    • Patel, Yuval A., Jacqueline B. Henson, Julius M. Wilder, Jiayin Zheng, Shein-Chung Chow, Carl L. Berg, and Andrew J. Muir. “The Impact of HLA Serotyping and HLA Matching for PSC, PSC/AIH, AIH, PBC/AIH, and PBC Patients on Post-Liver Transplant Graft Failure: an Analysis of the UNOS Database.” In Hepatology, 64:500A-500A. WILEY, 2016.
       Link to Item
    • Sena, Arlene C., Alison Hilton, Christopher B. Hurt, Heidi Swygard, Claire Farel, David Wohl, and Andrew J. Muir. “Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program.” In Hepatology, 64:867A-867A. WILEY, 2016.
       Link to Item
    • Charlton, Michael R., Nezam H. Afdhal, Macky Natha, Luisa M. Stamm, Stacey M. Lee, Diana M. Brainard, John G. McHutchison, Paul B. Watkins, and Andrew J. Muir. “Detecting DILI in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and-2 Studies.” In Transplantation, 100:S136–S136. LIPPINCOTT WILLIAMS & WILKINS, 2016.
       Link to Item
    • Charlton, Michael R., Jacqueline G. O’Leary, Natalie H. Bzowej, Andrew J. Muir, Kevin M. Korenblat, Jonathan M. Fenkel, K Rajender Reddy, et al. “Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study.” In Hepatology, 62:1387A-1388A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Bowlus, Christopher L., Keyur Patel, Indra Neil Guha, Roger W. Chapman, Olivier Chazouilleres, Naga P. Chalasani, John M. Vierling, et al. “Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab.” In Hepatology, 62:519A-519A. WILEY-BLACKWELL, 2015.
       Link to Item
    • French, Dorothy, Zachary D. Goodman, Erik G. Huntzicker, David Newstrom, Satyajit Karnik, Victoria Smith, Raul E Aguilar Schall, et al. “Expression of matrix metalloproteinase 9 (MMP9) and the apoptosis signal-regulating kinase 1 (ASK1) pathway activation marker, phospho-P38 (p-P38), in primary sclerosing cholangitis (PSC).” In Hepatology, 62:523A-524A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Harrison, Stephen A., Zachary D. Goodman, Vlad Ratziu, Rohit Loomba, Anna Mae Diehl, Eric Lawitz, Holger Hinrichsen, et al. “Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:910A-910A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Manns, Michael P., Bertus Eksteen, Mitchell L. Shiffman, Cynthia Levy, Kris V. Kowdley, Aldo J. Montano-Loza, Harry L. Janssen, et al. “Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC).” In Hepatology, 62:515A-515A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Mayo, Marlyn J., Alan J. Wigg, Alex J. Thompson, Stuart K. Roberts, Hays Arnold, Tarek I. Hassanein, Barbara A. Leggett, et al. “Impact of NGM282 on the Incidence and Severity of Pruritus in Primary Biliary Cirrhosis Patients and Correlations with Liver Chemistries and Serum Bile Acids.” In Hepatology, 62:520A-521A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Mayo, Marlyn J., Alan J. Wigg, Stuart K. Roberts, Hays Arnold, Tarek I. Hassanein, Barbara A. Leggett, John P. Bate, et al. “NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial.” In Hepatology, 62:263A-264A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Muir, Andrew J., Michael R. Charlton, Phillip S. Pang, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Nezam H. Afdhal, and Paul B. Watkins. “Detecting Drug-Induced Liver Injury in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies.” In Hepatology, 62:257A-258A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Ratziu, Vlad, Arun J. Sanyal, Rohit Loomba, Stephen H. Caldwell, Reem H. Ghalib, Dawn M. Torres, Arthur J. McCullough, et al. “Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).” In Hepatology, 62:1298A-1299A. WILEY-BLACKWELL, 2015.
       Link to Item
    • Reau, Nancy, Andrew J. Muir, Paul Pockros, K Rajender Reddy, Marcos Pedrosa, Lois Larsen, Jeffrey Enejosa, and Charles Howell. “High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r plus Dasabuvir +/- Ribavirin: Integrated Safety and Efficacy Analysis.” In American Journal of Gastroenterology, 110:S859–S859. NATURE PUBLISHING GROUP, 2015.
       Link to Item
    • Charlton, Michael, Didier Samuel, Edward Gane, Robert S. Brown, Michael P. Curry, Paul Kwo, Robert Fontana, et al. “Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection after Liver Transplantation: Results of a Prospective, Multicenter Study..” In Liver Transplantation, 20:S125–S125. WILEY-BLACKWELL, 2014.
       Link to Item
    • Jacobson, Ira M., Patrick Marcellin, Alessandra Mangia, Paul Y. Kwo, Graham Foster, Maria Buti, Norbert Brau, et al. “All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study.” In Gastroenterology, 146:S903–S903. W B SAUNDERS CO-ELSEVIER INC, 2014.
       Link to Item
    • Kowdley, Kris V., Stuart C. Gordon, K Rajender Reddy, Lorenzo Rossaro, David Bernstein, Di An, Evguenia Svarovskaia, et al. “Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study.” In Gastroenterology, 146:S926–S926. W B SAUNDERS CO-ELSEVIER INC, 2014.
       Link to Item
    • Moylan, Cynthia A., Kouros Owzar, Andrew J. Muir, Francois Cauchy, Jacques Belghiti, Anna Mae Diehl, and Valerie Paradis. “Gene Expression and Pathway Analyses Reveal Distinctions Between Hepatocellular Carcinoma Arising in Fibrotic and Non-Fibrotic Nonalcoholic Fatty Liver Disease.” In Gastroenterology, 146:S998–99. W B SAUNDERS CO-ELSEVIER INC, 2014.
       Link to Item
    • Brown, Cristal L., Bradley G. Hammill, Laura G. Qualls, Lesley H. Curtis, and Andrew J. Muir. “High morbidity and mortality in end-stage liver disease and heart failure.” In Hepatology, 60:964A-965A. WILEY-BLACKWELL, 2014.
       Link to Item
    • Jeffers, Lennox J., Julius M. Wilder, Andrew J. Muir, Charles Howell, Yanni Zhu, Star Seyedkazemi, Jenny C. Yang, Phillip S. Pang, John G. McHutchison, and K Rajender Reddy. “Safety and Efficacy of Ledipasvir/Sofosbuvir Single-Tablet-Regimen in African Americans with Genotype 1 Chronic Hepatitis C Virus: A Retrospective Analysis of Phase 3 Studies.” In Hepatology, 60:319A-320A. WILEY-BLACKWELL, 2014.
       Link to Item
    • Jensen, Donald M., Jacqueline G. O’Leary, Paul J. Pockros, Kenneth E. Sherman, Paul Y. Kwo, Mark E. Mailliard, Kris V. Kowdley, et al. “Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort.” In Hepatology, 60:219A-220A. WILEY-BLACKWELL, 2014.
       Link to Item
    • Jou, Janice H., Lauren A. Beste, Yin Yang, Michael F. Chang, and Andrew J. Muir. “Specialty Care is Associated with Early Diagnosis of Hepatitis C-related Hepatocellular Carcinoma in US Veterans.” In Hepatology, 60:839A-839A. WILEY-BLACKWELL, 2014.
       Link to Item
    • Oloruntoba, Omobonike O., Julius M. Wilder, Alastair D. Smith, Andrew J. Muir, and Cynthia A. Moylan. “The Influence of Race on Patient Preferences and Access to Orthotopic Liver Transplantation and Organ Donation.” In Hepatology, 60:963A-963A. WILEY-BLACKWELL, 2014.
       Link to Item
    • Charlton, Michael R., Edward J. Gane, Michael P. Manns, Robert S. Brown, Michael P. Curry, Paul Y. Kwo, Robert J. Fontana, et al. “Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study.” In Hepatology, 58:1378A-1378A. WILEY-BLACKWELL, 2013.
       Link to Item
    • Jazwinski, Alison B., Paul J. Clark, Alexander J. Thompson, Stuart C. Gordon, Eric J. Lawitz, Stephanie Noviello, Clifford A. Brass, et al. “Predictors of consent to pharmacogenomics testing in the IDEAL study..” In Pharmacogenet Genomics, 23:619–23, 2013. https://doi.org/10.1097/FPC.0000000000000002.
       Full Text  Link to Item
    • Gordon, Stuart C., Andrew J. Muir, Joseph K. Lim, Brian Pearlman, Curtis K. Argo, Guy W. Neff, Ananthakrishnan Ramani, et al. “The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study.” In Hepatology, 58:1104A-1105A. WILEY-BLACKWELL, 2013.
       Link to Item
    • Muir, Andrew J., Claire Jurkowski, Elizabeth L. Cooney, Jan L. Hillson, Max Lataillade, Veronica Mas Casullo, Todd Gray, Dong Xu, Logesvaran Yogendran, and Subasree Srinivasan. “Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies.” In Hepatology, 58:744A-745A. WILEY-BLACKWELL, 2013.
       Link to Item
    • Afdhal, Nezam, Edoardo G. Giannini, Samuel Sigal, Andrew J. Muir, K Rajender Reddy, I-Shyan Sheen, Shanthi Vijayaraghavan, et al. “Improved SVR in a unique cohort of non-cirrhotic thrombocytopenic patients with hepatitis C virus (HCV) treated in the global multicenter ENABLE 1 and 2 trials.” In Hepatology, 56:995A-995A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Clark, Paul J., Rosanna Santoro, Valeria Piazzolla, Leonardo Mottola, D. Bacca, N. Dello Iacono, Salvatore Grimaldi, et al. “Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C.” In Hepatology, 56:1028A-1029A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Devine, Scott, Michael W. Kattan, Andrew J. Muir, Lisa Pedicone, Fred Poordad, Thierry Poynard, Mark S. Sulkowski, and Alexander J. Thompson. “Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR).” In Hepatology, 56:1052A-1052A. WILEY, 2012.
       Link to Item
    • Jones, Lisa, Natravis Cox, Scharles Konadu, Stephanie W. Brinson, and Andrew J. Muir. “Automated Extraction of Quality Indicators for Hospitalized patients with cirrhosis and ascites.” In Hepatology, 56:1083A-1083A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Muir, Andrew J., Jan L. Hillson, Todd E. Gray, Dong Xu, Laura Ishak, Jeremy A. Freeman, David Fontana, Arantxa Horga, and Juan Carlos Lopez-Talavera. “Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b.” In Hepatology, 56:299A-299A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Muir, Andrew J., Maribel Rodriguez-Torres, Katyna Borroto-Esoda, Michael Peel, Sam Hopkins, and Yves Ribeill. “Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients.” In Hepatology, 56:234A-235A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Muir, Andrew J., Subasree Srinivasan, Sandhya Sapra, Dessislava Dimitrova, Jan L. Hillson, and Juan Carlos Lopez-Talavera. “Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa).” In Hepatology, 56:578A-579A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Saraswathula, Anirudh, Julius M. Wilder, and Andrew J. Muir. “A Systematic Review of Racial and Ethnic Diversity of Hepatitis C Virus Clinical Trials.” In Hepatology, 56:1087A-1087A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Shiffman, Mitchell L., Andrew J. Muir, John M. Vierling, Stuart C. Gordon, Marcelo Kugelmas, George Y. Wu, Tuan T. Nguyen, et al. “GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T.” In Hepatology, 56:570A-571A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Thompson, Alexander J., Mitchell L. Shiffman, Lorenzo Rossaro, Reem Ghalib, Steven-Huy B. Han, Kimberly L. Beavers, Stephen Pianko, et al. “Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial.” In Hepatology, 56:556A-557A. WILEY-BLACKWELL, 2012.
       Link to Item
    • Clark, Paul J., Alexander J. Thompson, Alison Jazwinski, Hans L. Tillmann, Susanna Naggie, Andrew J. Muir, and Keyur Patel. “Association of Serum Adipocytokines With IL28B and SVR in Chronic Hepatitis C.” In Gastroenterology, 142:S968–69. W B SAUNDERS CO-ELSEVIER INC, 2012.
       Link to Item
    • Clark, Paul J., Alexander J. Thompson, David M. Vock, Lisa E. Kratz, Adviye A. Tolun, Hao Yue Zhang, Andrew J. Muir, et al. “METABOLOMIC ANALYSIS DEMONSTRATES HEPATITIS C VIRUS GENOTYPES G2/3 SELECTIVELY PERTURB DISTAL STEPS IN CHOLESTEROL BIOSYNTHESIS.” In Hepatology, 54:1333A-1333A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Clark, Paul J., Alexander J. Thompson, Thomas J. Urban, Keyur Patel, David M. Vock, Qianqian Zhu, Alison Jazwinski, et al. “PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC).” In Hepatology, 54:402A-402A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Gellad, Ziad F., Susanna Naggie, Shelby D. Reed, Paul J. Clark, Alex J. Thompson, Kevin A. Schulman, and Andrew J. Muir. “THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM.” In Hepatology, 54:417A-418A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Jazwinski, Alison, Paul J. Clark, Hans L. Tillmann, and Andrew J. Muir. “VITAMIN D AND TREATMENT RESPONSE IN AFRICAN AMERICAN PATIENTS WITH HCV GENOTYPE 1.” In Hepatology, 54:853A-854A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Muir, Andrew J., Bruce R. Bacon, Norman Gitlin, Marcelo Kugelmas, Hans L. Tillman, Eric A. Grovender, Bill Van Antwerp, Sarah Mische, and Paul Y. Kwo. “INTERFERON alpha-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS.” In Hepatology, 54:1439A-1439A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Rabiee, Atoosa, Hans L. Tillmann, F Fred Poordad, Eric Lawitz, Mitchell L. Shiffman, Andrew J. Muir, Stephanie Noviello, et al. “INFLUENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE-1 (G1) SUBTYPE, BASELINE VIRAL LOAD AND IL28B GENOTYPE ON PEGINTERFERON (PEG)/RIBAVIRIN (RBV) TREATMENT RESPONSE: RESULTS OF THE IDEAL STUDY.” In Hepatology, 54:998A-999A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Thompson, Alexander J., Paul J. Clark, David M. Vock, Ruth Pfeiffer, Hans L. Tillmann, Keyur Patel, Susanna Naggie, et al. “PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS.” In Hepatology, 54:803A-804A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Thompson, Alexander J., Paul J. Clark, Hans L. Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, et al. “IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” In Hepatology, 54:436A-437A. WILEY-BLACKWELL, 2011.
       Link to Item
    • Smith, Alastair D., Andrew J. Muir, Michael A. Morse, Paul V. Suhocki, and Kadiyala V. Ravindra. “Liver Transplantation Following Down-Staging of a Large Primary Liver Tumor Associated with a Very High Serum Alpha Fetoprotein Concentration.” In Liver Transplantation, 17:S275–76. WILEY-BLACKWELL, 2011.
       Link to Item
    • Gellad, Ziad F., Shelby Reed, Andrew J. Muir, John McHutchison, William Steven, Ala I. Sharara, Kimberly Ann A. Brown, et al. “Truncated Therapy Based on Rapid Virologic Response is a Cost Effective Treatment Paradigm for Chronic Hepatitis C.” In Gastroenterology, 140:S895–S895. W B SAUNDERS CO-ELSEVIER INC, 2011.
       Link to Item
    • Clark, Paul J., Alexander J. Thompson, Mingfu Zhu, Qianqian Zhu, Dongliang Ge, Mark S. Sulkowski, Hans L. Tillmann, et al. “IL28B GENETIC POLYMORPHISM HAS GENOME WIDE SIGNIFICANT ASSOCIATIONS WITH SERUM LOW DENSITY LIPOPROTEIN LEVELS AND HEPATIC STEATOSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC).” In Hepatology, 52:439A-440A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Jacobson, Ira M., John G. McHutchison, Geoffrey M. Dusheiko, Adrian M. Di Bisceglie, Rajender Reddy, Natalie H. Bzowej, Patrick Marcellin, et al. “TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY.” In Hepatology, 52:427A-427A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Lawitz, Eric, Maribel Rodriguez-Torres, Vinod K. Rustgi, Tarek Hassanein, Mohamad H. Rahimy, Constance A. Crowley, James L. Freddo, Andrew J. Muir, and John G. McHutchison. “SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS.” In Hepatology, 52:334A-335A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Muir, Andrew J. “SS7-5 Genetic variation in IL28B and hepatitis C outcomes.” In Cytokine, 52:49–49. Elsevier BV, 2010. https://doi.org/10.1016/j.cyto.2010.07.203.
       Full Text
    • Muir, Andrew J., Eric Lawitz, Maribel Rodriguez-Torres, Vinod K. Rustgi, Tarek Hassanein, James R. Appleman, Constance A. Crowley, James L. Freddo, and John G. McHutchison. “IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS.” In Hepatology, 52:1200A-1200A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Muir, Andrew J., Eric Lawitz, Reem H. Ghalib, Norman L. Sussman, Frank Anderson, Gregory T. Everson, Ira M. Jacobson, et al. “PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12.” In Hepatology, 52:715A-716A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Rodriguez-Torres, Maribel, Reem H. Ghalib, Stuart C. Gordon, Eric Lawitz, Keyur Patel, Ronald Pruitt, Aasim M. Sheikh, et al. “IMO-2125, A TLR9 AGONIST, INDUCES IMMUNE RESPONSES WHICH CORRELATE WITH REDUCTIONS IN VIRAL LOAD IN NULL RESPONDER HCV PATIENTS.” In Hepatology, 52:336A-336A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Sulkowski, Mark S., Stephen A. Harrison, Lorenzo Rossaro, Ke-Qin Hu, Eric Lawitz, Mitchell L. Shiffman, Andrew J. Muir, et al. “IMPAIRED FASTING GLUCOSE IS ASSOCIATED WITH LOWER RATES OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC): RETROSPECTIVE ANALYSIS OF THE IDEAL STUDY.” In Hepatology, 52:712A-712A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Thompson, Alexander J., Abanish Singh, Jacques Fellay, Dongliang Ge, Mark S. Sulkowski, Andrew J. Muir, Hans L. Tillmann, et al. “GENOME-WIDE ASSOCIATION STUDY IDENTIFIES AN ASSOCIATION BETWEEN ITPA GENE VARIANTS AND IFN-INDUCED THROMBOCYTOPENIA IN CHRONIC HEPATITIS C PATIENTS FROM THE IDEAL STUDY.” In Hepatology, 52:362A-363A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, et al. “HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE.” In Hepatology, 52:708A-709A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Thompson, Alexander J., Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mark S. Sulkowski, Andrew J. Muir, et al. “COMMON GENETIC VARIANTS DO NOT ASSOCIATE WITH IFN-INDUCED NEUTROPENIA IN A GENOME-WIDE ASSOCIATION STUDY OF CHRONIC HEPATITIS C PATIENTS IN THE IDEAL STUDY.” In Hepatology, 52:764A-765A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Thompson, Alexander J., Paul J. Clark, Jacques Fellay, Andrew J. Muir, Hans L. Tillmann, Keyur Patel, Susanna Naggie, et al. “IL28B GENOTYPE IS NOT ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY.” In Hepatology, 52:437A-438A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Thompson, Alexander J., Paul J. Clark, Mingfu Zhu, Qianqian Zhu, Dongliang Ge, Mark S. Sulkowski, Andrew J. Muir, et al. “GENOME WIDE-ASSOCIATION STUDY IDENTIFIES IL28B POLYMORPHISM TO BE ASSOCIATED WITH BASELINE ALT AND HEPATIC NECRO-INFLAMMATORY ACTIVITY IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY.” In Hepatology, 52:1220A-1221A. WILEY-BLACKWELL, 2010.
       Link to Item
    • Lawitz, Eric J., Atif Zaman, Andrew J. Muir, Mitchell L. Shiffman, Boris Yoffe, Tracy Zhang, Sherri Souza, and Diana F. Hausman. “INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN.” In Hepatology, 48:385A-385A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Lawitz, Eric, Andrew J. Muir, Fred Poordod, Eric Chun, and Janet Hammond. “TREATMENT WEEK 24 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAiVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS.” In Hepatology, 48:433A-434A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • McCone, Jonathan, Ke-Qin Hu, John G. McHutchison, Mitchell L. Shiffman, John W. King, Steven K. Herrine, Greg Wayne Goller, et al. “SUSTAINED VIROLOGIC RESPONSE (SVR) AND PREDICTORS OF RESPONSE IN AFRICAN AMERICAN (AA) PATIENTS IN THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE 3B STUDY.” In Hepatology, 48:430A-431A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • McHutchison, John G., Mitchell L. Shiffman, Norah Terrault, Michael P. Manns, Adrian M. Di Bisceglie, Ira M. Jacobson, Nezom H. Afdhal, et al. “A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS.” In Hepatology, 48:431A-432A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Moylan, Cynthia A., Steve S. Choi, Chaitanya R. Acharya, Kelly Salter, Andrew J. Muir, Anil Potti, and Anna Mae Diehl. “GENE EXPRESSION PROFILES COUPLED WITH SIGNATURES OF ONCOGENIC PATHWAY DYSREGULATION PROVIDE A RATIONAL APPROACH TO DISSECTING THE MOLECULAR HETEROGENEITY OF HEPATOCELLULAR CARCINOMA.” In Hepatology, 48:1120A-1120A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Muir, Andrew J., Eric J. Lawitz, John G. McHutchison, Stuart C. Gordon, Ira M. Jacobson, Bambang S. Adiwijaya, Leif Bengtsson, Lindsay McNair, and Maribel Rodriguez-Torres. “VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C.” In Hepatology, 48:1131A-1132A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Nyberg, Lisa M., Mitchell L. Shiffman, Hector Bonilla, Ke-Qin Hu, Timothy R. Morgan, Robert A. Levine, Eric J. Lawitz, et al. “PREDICTING THE ABILITY TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE (SVR) IN THE FIRST 12 WEEKS: RESULTS FROM THE IDEAL STUDY.” In Hepatology, 48:1134A-1134A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Poordad, Fred, Norbert Brau, Eric J. Lawitz, Mitchell L. Shiffman, John G. McHutchison, Andrew J. Muir, Greg Wayne Galler, et al. “HEMATOLOGIC SAFETY DATA FROM THE IDEAL TRIAL: NEUTROPENIA, ANEMIA AND THROMBOCYTOPENIA PROFILES OF PEGINTERFERON ALFA/RIBAVIRIN.” In Hepatology, 48:1145A-1145A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Shiffman, Mitchell L., Thomas Berg, F Fred Poordad, Jean-Pierre Bronowicki, Andrew J. Muir, Stuart C. Gordon, Shelley George, Nathalie Adda, and John G. McHutchison. “A STUDY OF TELAPREVIR COMBINED WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN SUBJECTS WITH WELL-DOCUMENTED NON-RESPONSE OR RELAPSE AFTER PREVIOUS PEGINTERFERON-ALFA-2A AND RIBAVIRIN TREATMENT: INTERIM ANALYSIS.” In Hepatology, 48:1135A-1136A. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Gentile, Judith W., Joseph C. Shanahan, Andrew J. Muir, and Alastair D. Smith. “DISTAL SYMMETRICAL MYOPATHY IN THE SETTING OF PEGYLATED INTERFERON ALFA AND RIBAVIRIN THERAPY FOLLOWING LIVER TRANSPLANTATION..” In Liver Transplantation, 14:S186–S186. JOHN WILEY & SONS INC, 2008.
       Link to Item
    • Smith, Alastair D., Judith W. Gentile, Andrew J. Muir, and David N. Howell. “DE NOVO AUTOIMMUNE HEPATITIS IN THE AFTER MATH OF SUCCESSFUL COMBINATION ANTI-VIRAL THERAPY FOR RECURRENT HEPATITIS C VIRUS LIVER DISEASE..” In Liver Transplantation, 14:S87–S87. WILEY-BLACKWELL, 2008.
       Link to Item
    • Lee, Noel M., Andrew J. Muir, and Carla W. Brady. “The Readability of Hepatitis C Health Education Materials.” In American Journal of Gastroenterology, 102:S430–S430. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.14309/00000434-200709002-00846.
       Full Text
    • Robertson, Katina D., Cynthia A. Moylan, Carla W. Brady, and Andrew J. Muir. “Factors Influencing Participation in Hepatitis C Research Trials.” In American Journal of Gastroenterology, 102:S224–S224. Ovid Technologies (Wolters Kluwer Health), 2007. https://doi.org/10.14309/00000434-200709002-00296.
       Full Text
    • Brady, Carla W., Alastair D. Smith, Karen M. Stechuchak, Cynthia J. Coffman, Janet E. Tuttle-Newhall, Dawn Provenzale, and Andrew J. Muir. “Predictors of the development of de novo hepatocellular carcinoma (HCC) in patients awaiting orthotopic liver transplantation (OLT) during the meld era.” In Hepatology, 44:506A-507A. JOHN WILEY & SONS INC, 2006.
       Link to Item
    • Gellad, Ziad F., Barbara D. Alexander, Jesse K. Liu, Brian C. Griffith, Angela M. Meyer, Jeff L. Johnson, and Andrew J. Muir. “Severity of Clostridium difficile associated diarrhea in solid-organ transplant patients.” In American Journal of Gastroenterology, 101:S198–S198. NATURE PUBLISHING GROUP, 2006.
       Link to Item
    • Muir, Andrew J., John G. McHutchison, Keyur Patel, Greg Clary, and Jane P. Gagliardi. “Sertaline for the prevention of depression with HCV therapy.” In American Journal of Gastroenterology, 101:S163–64. NATURE PUBLISHING GROUP, 2006.
       Link to Item
    • Muir, Andrew J., Pamela B. Sylvestre, and Don C. Rockey. “Interferon gamma-1b for the treatment of chronic hepatitis C infection.” In Gastroenterology, 124:A718–A718. Elsevier BV, 2003. https://doi.org/10.1016/s0016-5085(03)83626-0.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.